OIE Reference Laboratory Reports ActivitiesActivities in 2021

This report has been submitted: 2022-01-19 13:21:25

| Name of disease (or topic) for which you are a designated OIE Reference Laboratory: | Contagious bovine pleuropneumonia |
|---|--|
| Address of laboratory: | Campus International de Baillarguet TA A-117/E 34398 Montpellier Cedex 5 FRANCE |
| Tel.: | +33 (0)4 67 59 37 39 |
| Fax: | |
| E-mail address: | lucia.manso-silvan@cirad.fr |
| Website: | http://umr-astre.cirad.fr |
| Name (including Title) of Head of Laboratory (Responsible Official): | Dr Nathalie Vachiery |
| Name (including Title and Position) of OIE Reference Expert: | Lucia Manso-Silvan |
| Which of the following defines your laboratory? Check all that apply: | Governmental |

ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

| Diagnostic Test | Indicated in OIE Manual (Yes/No) | Total number of te | est performed last year |
|---------------------------|-------------------------------------|--------------------|-------------------------|
| Indirect diagnostic tests | | Nationally | Internationally |
| CBPP cELISA | Yes | 0 | 4 |
| Direct diagnostic tests | | Nationally | Internationally |
| PCR | Yes | | 4 |
| qPCR | Yes | | 1 |
| isolation | Yes | | 3 |

ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.

To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

| Type of reagent available | Related diagnostic test | Produced/ provide | Amount supplied nationally (ml, mg) | Amount supplied internationally (ml, mg) | No. of recipient OIE Member Countries | Region of recipients |
|---------------------------|-------------------------------|----------------------|--|---|---|---|
| Antigen | cELISA | produced | 20 | 0 | 1 | □Africa □Americas □Asia and Pacific □Europe □Middle East |
| Reference serum | cELISA | produced | 10 | 3 | 2 | □Africa □Americas □Asia and Pacific □Europe □Middle East |
| CFT kit | CFT | produced | 0 | 13 kits 1000 | 2 | □Africa □Americas □Asia and Pacific □Europe □Middle East |
| Reference DNA | PCR | produced | 0 | 3 | 1 | □Africa □Americas □Asia and Pacific □Europe □Middle East |
| Medium supplement | isolation | produced | 0 | 900 | 1 | Africa Americas Asia and Pacific Europe Middle East |

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

Yes

| Vaccine name | Amount supplied nationally (ml, mg) (including for own use) | Amount supplied to other countries (ml, mg) | Name of recipient OIE Member Countries |
|--------------|---|---|---|
| T1/44 | 0 | 2 | MAURITANIA |
| T1sr | 0 | 1 | MAURITANIA |

ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

Yes

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

| Name of the new test or diagnostic method or vaccine developed | Description and References (Publication, website, etc.) |
|--|---|
| New qPCR assay | ongoing |

ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

| Name of OIE Member Country seeking assistance | Date (month) | No. samples received for provision of diagnostic support | No. samples received for provision of confirmatory diagnoses |
|---|----------------|--|--|
| THE NETHERLANDS | June 2021 | 4 | 24 |
| THE NETHERLANDS | July 2021 | 4 | 4 |
| THE NETHERLANDS | July 2021 | 13 | 33 |
| MONGOLIA | September 2021 | 0 | 13 |

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

| Name of the OIE Member Country receiving a technical consultancy | Purpose | How the advice was provided |
|--|--|-----------------------------|
| UGANDA | USAID-funded APOLOU/Resilience Challenge Fund (RCF) project | answer to questionaire |

ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

| Title of the study | Duration | Purpose of the study | Partners (Institutions) | OIE Member Countries involved other than your country |
|--------------------|----------|--|----------------------------|--|
| PRAPS 1/OIE | 5 years | Assessment of CBPP vaccination campaigns by titration and seromonitoring | OIE, LCV, ISRA, CIRDES | NIGER |

ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

| If the answer is yes, please provide details of the data collected: | |
|---|--|
| Analysis of seromonitoring data from PRAPS/OIE project. | |

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

| If the answer is no, please provide a brief explanation of the situation: |
|---|
| Publication process ongoing |

13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)

a) Articles published in peer-reviewed journals: 1

Ngounda, P., L. Manso-Silván, F. Thiaucourt (2021). Situation actuelle de la péripneumonie contagieuse bovine en République Centrafricaine. Revue MTSI, 8p. DOI: 10.48327/mtsibulletin.2021.100

b) International conferences: 2

Vicki Chalker, Mitchell Balish, Assunta Bertaccini, Alain Blanchard, Daniel R. Brown, Joachim Frey, Gail Gasparich, Ludwig Hoelzle, Christine Knox, Chih-Horng Kuo, Lucia Manso-Silvan, et al (2021). Mycoplasma taxonomy: what's in a name and where to submit? XXIII Biennial Congress of the International Organization for Mycoplasmology (IOM), November 2021.

Jores J, Baldwin C, Blanchard A, Browning GF, Colston A, Gerdts V, et al. (2021) Contagious Bovine and Caprine Pleuropneumonia: a research community's recommendations for the development of better vaccines. XXIII Biennial Congress of the International Organization for Mycoplasmology (IOM), November 2021.

- c) National conferences: 0
- d) Other:

(Provide website address or link to appropriate information) 0

ToR 7: To provide scientific and technical training for personnel from OIE Member Countries

To recommend the prescribed and alternative tests or vaccines as OIE Standards

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 1b) Seminars: 0

c) Hands-on training courses: 1 d) Internships (>1 month): 0

| Type of technical training provided (a, b, c or d) | Country of origin of the expert(s) provided with training | No. participants from the corresponding country |
|--|---|---|
| С | Mauritania | 6 |
| a | Kenya | 2 |

ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned

15. Does your laboratory have a Quality Management System?

Yes

| Quality management system adopted | Certificate scan (PDF, JPG, PNG format) |
|-----------------------------------|---|
| ISO17025 | 1-2207.pdf |

16. Is your quality management system accredited?

Yes

| Test for which your laboratory is accredited | Accreditation body |
|--|--------------------|
| cELISA (flexible) | COFRAC |

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)

ToR 9: To organise and participate in scientific meetings on behalf of the OIE

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing see point 1.3

| Purpose for inter-laboratory test comparisons ¹ | No. participating laboratories | Region(s) of participating OIE Member Countries |
|--|-----------------------------------|--|
| CBPP cELISA | 2 | |

ToR 12: To place expert consultants at the disposal of the OIE

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

| Kind of consultancy | Location | Subject (facultative) |
|---------------------|----------|---|
| OIE ad hoc Group | virtual | Evaluation of Contagious Bovine Pleuropneumonia Status of Members |

25. Additional comments regarding your report: